Celon Pharma S.A. (WSE:CLN)
Poland · Delayed Price · Currency is PLN 21.80
-0.20 (-0.91%)
Oct 24, 2025, 5:03 PM CET
Celon Pharma Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 187.89 | 176.62 | 164.39 | 161.92 | 169.56 | 135.48 | Upgrade |
Other Revenue | 18.33 | 28.93 | 50.27 | 31.97 | 26.53 | 21.97 | Upgrade |
| 206.22 | 205.55 | 214.66 | 193.89 | 196.09 | 157.45 | Upgrade | |
Revenue Growth (YoY) | -0.78% | -4.25% | 10.72% | -1.12% | 24.54% | 53.99% | Upgrade |
Cost of Revenue | 72.42 | 63.17 | 66.82 | 66.46 | 61.72 | 36.64 | Upgrade |
Gross Profit | 133.79 | 142.38 | 147.85 | 127.42 | 134.37 | 120.81 | Upgrade |
Selling, General & Admin | 124.84 | 120.04 | 111.12 | 107.7 | 90.11 | 83.44 | Upgrade |
Other Operating Expenses | 17.77 | 21.98 | 15.06 | 13.52 | 13.5 | 6.93 | Upgrade |
Operating Expenses | 195.24 | 195.31 | 176.2 | 165.32 | 144.96 | 124.91 | Upgrade |
Operating Income | -61.44 | -52.94 | -28.35 | -37.9 | -10.59 | -4.1 | Upgrade |
Interest Expense | -2.08 | -2.47 | -2.66 | -1.67 | -1.55 | -0.67 | Upgrade |
Interest & Investment Income | 0.31 | 0.16 | 0.37 | 1.85 | 0.08 | 0.14 | Upgrade |
Earnings From Equity Investments | -20.12 | -5.55 | - | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -0.08 | -0.4 | 0.03 | -0.4 | -2.59 | -0.64 | Upgrade |
Other Non Operating Income (Expenses) | 3.75 | 5.7 | 9.53 | 1.11 | -0.57 | -0.75 | Upgrade |
EBT Excluding Unusual Items | -79.67 | -55.49 | -21.08 | -37.01 | -15.22 | -6.02 | Upgrade |
Gain (Loss) on Sale of Assets | 0.68 | 0.68 | 1.11 | 0.56 | 0.13 | 0.43 | Upgrade |
Asset Writedown | 13.19 | 15.45 | - | - | - | - | Upgrade |
Pretax Income | -65.8 | -39.37 | -19.97 | -36.45 | -15.09 | -5.59 | Upgrade |
Income Tax Expense | 3.09 | -4.92 | 8.16 | 2.83 | -3.48 | -4.67 | Upgrade |
Net Income | -68.88 | -34.45 | -28.12 | -39.28 | -11.61 | -0.92 | Upgrade |
Net Income to Common | -68.88 | -34.45 | -28.12 | -39.28 | -11.61 | -0.92 | Upgrade |
Shares Outstanding (Basic) | 53 | 53 | 51 | 51 | 47 | 45 | Upgrade |
Shares Outstanding (Diluted) | 53 | 53 | 51 | 51 | 47 | 45 | Upgrade |
Shares Change (YoY) | 0.08% | 2.86% | 0.04% | 9.32% | 3.74% | - | Upgrade |
EPS (Basic) | -1.31 | -0.66 | -0.55 | -0.77 | -0.25 | -0.02 | Upgrade |
EPS (Diluted) | -1.32 | -0.66 | -0.55 | -0.77 | -0.25 | -0.02 | Upgrade |
Free Cash Flow | -53.44 | -34.13 | -41.13 | -38.61 | 2.6 | -27.74 | Upgrade |
Free Cash Flow Per Share | -1.02 | -0.65 | -0.81 | -0.76 | 0.06 | -0.62 | Upgrade |
Dividend Per Share | - | - | 0.080 | 0.090 | 0.290 | 0.070 | Upgrade |
Dividend Growth | - | - | -11.11% | -68.97% | 314.29% | -12.50% | Upgrade |
Gross Margin | 64.88% | 69.27% | 68.87% | 65.72% | 68.53% | 76.73% | Upgrade |
Operating Margin | -29.80% | -25.75% | -13.21% | -19.55% | -5.40% | -2.60% | Upgrade |
Profit Margin | -33.40% | -16.76% | -13.10% | -20.26% | -5.92% | -0.58% | Upgrade |
Free Cash Flow Margin | -25.91% | -16.61% | -19.16% | -19.91% | 1.33% | -17.62% | Upgrade |
EBITDA | -30.66 | -14.97 | 8.63 | -2.57 | 27.84 | 25.49 | Upgrade |
EBITDA Margin | -14.87% | -7.29% | 4.02% | -1.33% | 14.20% | 16.19% | Upgrade |
D&A For EBITDA | 30.78 | 37.96 | 36.99 | 35.33 | 38.43 | 29.59 | Upgrade |
EBIT | -61.44 | -52.94 | -28.35 | -37.9 | -10.59 | -4.1 | Upgrade |
EBIT Margin | -29.80% | -25.75% | -13.21% | -19.55% | -5.40% | -2.60% | Upgrade |
Revenue as Reported | 207.18 | 207.19 | 216.57 | 194.59 | 199.11 | 159.99 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.